Developer docs
API playgroundTry for free, no card

Search company profiles

Genedrive

Full company profile

uuid000646f

Namestring
Genedrive
Legal namestring
Genedrive Diagnostics Ltd
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Genedrive Diagnostics Ltd is a Manchester-based pharmacogenetic testing company that develops and commercialises a point-of-care molecular diagnostic platform, the Genedrive® System, which delivers genetic test results at the bedside in approximately one hour. The platform supports two flagship assays: the MT-RNR1 ID Kit, which identifies infants at risk of antibiotic-induced hearing loss to inform aminoglycoside prescribing in neonatal intensive care, and the CYP2C19 ID Kit, which detects variants affecting clopidogrel metabolism to guide personalised antiplatelet therapy in stroke patients. Both assays were developed and validated in collaboration with NHS partners, and NHS Implementation Guides have been published for both products.

The company's commercial model is built on a hardware-plus-consumables razor-and-blade structure: it sells or places the Genedrive System instrument with NHS trusts and health boards and generates recurring revenue through ongoing sales of single-use test cartridges. Go-to-market is enterprise field sales targeting NHS neonatal units and stroke services, supported by clinical pilot programmes, implementation guides, and partnerships with Health Innovation Manchester, the University of Manchester, and the NHSE Network of Excellence in Pharmacogenetics. Pricing is not publicly disclosed and follows a quote-based model typical of medical-device procurement by NHS institutions. Strategic priorities include geographic expansion into Europe, the Middle East, and the US — with an FDA 510(k) submission for the CYP2C19 test anticipated around June 2026 — alongside manufacturing scale-up and product development, funded in part by a cluster of equity raises in 2024 and February 2026 totaling up to approximately £13 million, with insider participation from CEO Dr. Gino Miele, CFO Russ Shaw, and major shareholders David Nugent and Robert English.

Short descriptiontext

Genedrive is a Manchester-based pharmacogenetic diagnostics company that sells a point-of-care molecular platform and test kits to the UK NHS, enabling rapid bedside genetic testing for neonatal antibiotic safety and stroke antiplatelet therapy selection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersManchester, United Kingdom
HQ citystring
Manchester
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacogenetic testing, molecular diagnostics, point-of-care testing, personalised medicine, genetic test kits
Industry1 code
PRIMARYHSABALAO
Pharmacogenomics-Informed Medication Optimization Support
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Genedrive System Hardware Sales
TypeHardware Sales
Description

Sale of the Genedrive molecular diagnostic instrument/platform to healthcare institutions. The system serves as the hardware platform upon which test kits are run.

genedrive.com
2Test Kit Consumables
TypeOne Time License
Description

Recurring sales of MT-RNR1 ID Kit and CYP2C19 ID Kit test cartridges/consumables to NHS and healthcare customers as they conduct ongoing patient testing.

genedrive.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Genedrive System
Description

Molecular diagnostic platform for rapid pharmacogenetic testing at point of need.

genedrive.com
Core offering1 text field

Genedrive develops and commercialises a point-of-care molecular diagnostic platform (the Genedrive® System) that runs single-use pharmacogenetic test cartridges. Its two flagship kits — the MT-RNR1 ID Kit for personalised antibiotic selection in neonatal intensive care and the CYP2C19 ID Kit for personalised antiplatelet therapy in stroke — are sold to NHS trusts and other healthcare institutions, delivering genetic results in approximately one hour at the bedside.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Results delivered in approximately 1 hour vs days for traditional lab testing
Product overview1 text field

Genedrive is a pharmacogenetic testing company offering a point-of-care molecular diagnostic platform (Genedrive® System) with two flagship test kits: the MT-RNR1 ID Kit for personalised antibiotic treatment in neonates, and the CYP2C19 ID Kit for personalised antiplatelet treatment in stroke patients. The platform enables rapid genetic testing at the bedside within time-critical healthcare settings, with both products developed and validated in collaboration with NHS partners.

Product and service1 record
1Genedrive® System
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Manchester NHS Industry Partnership Programme
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-16
Description

Multi-partner grant initiative to validate the CYP2C19 ID Kit in NHS settings requiring rapid genomic testing. Part of a Manchester NHS Industry Partnership Programme focused on improving time-critical diagnostics in healthcare.

reuters.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with Health Innovation Manchester to support sustained deployment of the MT-RNR1 test across Greater Manchester. The partnership involves academic and health partners to ensure implementation across all neonatal sites in the region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership with University of Manchester for translational genomic medicine research and the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Leading molecular diagnostics platform (GeneXpert) widely deployed across hospitals including the NHS. Comparable as a point-of-care/hospital molecular diagnostics company; broader portfolio and deeper global footprint, but overlapping use cases in rapid genetic and infectious disease testing.

TypeDirect peer
Description

UK-based developer of a point-of-care molecular diagnostic platform (Q-POC) with similar focus on rapid, decentralised genetic testing. Directly comparable business model and target customer base (hospitals, including NHS-adjacent markets).

TypeDirect peer
Description

UK-headquartered diagnostics company with point-of-care and clinical laboratory molecular testing capabilities, including pharmacogenetics offerings. Comparable as a UK diagnostics peer serving NHS and international hospital markets.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-preparation company with a broad pharmacogenetics and infectious disease portfolio. Comparable in underlying molecular diagnostic technology, though operates at much larger scale across both research and clinical markets.

TypeBroad incumbent
Description

Subsidiary of bioMérieux offering rapid syndromic and molecular diagnostics used in hospital and emergency settings. Comparable in delivering rapid, panel-based molecular diagnostic results at the point of care within clinically actionable timeframes.

TypeBroad incumbent
Description

Now part of Roche, provides rapid molecular diagnostic systems (e.g., ePlex) for hospital and emergency care use. Comparable in deploying multi-analyte molecular panels at the hospital point of care, often in critical care and stroke workflows.

TypeBroad incumbent
Description

Acquired Agilent's molecular diagnostics and pharmacogenomics business (formerly GenMark Dx and others); provides clinical molecular testing platforms. Comparable in offering molecular diagnostics with pharmacogenomics focus into hospital and reference lab settings.

8Spartan Bioscience
TypeDirect peer
Description

Canadian developer of a point-of-care DNA testing platform (Spartan Cube) with pharmacogenomics and infectious disease applications. Closely comparable in delivering rapid, cartridge-based molecular diagnostics at the bedside for personalised medicine use cases.

TypeEmerging player
Description

US-based molecular diagnostics company with focus on pharmacogenomics and immune-related testing. Comparable in offering clinical-grade PGx testing, though primarily centralised laboratory rather than point-of-care delivery.

TypeBroad incumbent
Description

Global life sciences company with a clinical diagnostics division offering molecular testing instruments, reagents, and pharmacogenomics solutions. Comparable as a broad incumbent enabling hospital and reference-lab molecular and PGx testing at significantly larger scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genedrive

Molecular Diagnosticsgenedriveplc.com

Genedrive is a Manchester-based pharmacogenetic diagnostics company that sells a point-of-care molecular platform and test kits to the UK NHS, enabling rapid bedside genetic testing for neonatal antibiotic safety and stroke antiplatelet therapy selection.

What Genedrive does

Genedrive Diagnostics Ltd is a Manchester-based pharmacogenetic testing company that develops and commercialises a point-of-care molecular diagnostic platform, the Genedrive® System, which delivers genetic test results at the bedside in approximately one hour. The platform supports two flagship assays: the MT-RNR1 ID Kit, which identifies infants at risk of antibiotic-induced hearing loss to inform aminoglycoside prescribing in neonatal intensive care, and the CYP2C19 ID Kit, which detects variants affecting clopidogrel metabolism to guide personalised antiplatelet therapy in stroke patients. Both assays were developed and validated in collaboration with NHS partners, and NHS Implementation Guides have been published for both products.

The company's commercial model is built on a hardware-plus-consumables razor-and-blade structure: it sells or places the Genedrive System instrument with NHS trusts and health boards and generates recurring revenue through ongoing sales of single-use test cartridges. Go-to-market is enterprise field sales targeting NHS neonatal units and stroke services, supported by clinical pilot programmes, implementation guides, and partnerships with Health Innovation Manchester, the University of Manchester, and the NHSE Network of Excellence in Pharmacogenetics. Pricing is not publicly disclosed and follows a quote-based model typical of medical-device procurement by NHS institutions. Strategic priorities include geographic expansion into Europe, the Middle East, and the US — with an FDA 510(k) submission for the CYP2C19 test anticipated around June 2026 — alongside manufacturing scale-up and product development, funded in part by a cluster of equity raises in 2024 and February 2026 totaling up to approximately £13 million, with insider participation from CEO Dr. Gino Miele, CFO Russ Shaw, and major shareholders David Nugent and Robert English.

Genedrive firmographics

Firmographics
Name
Genedrive
Legal name
Genedrive Diagnostics Ltd
Website
https://genedriveplc.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Genedrive is a Manchester-based pharmacogenetic diagnostics company that sells a point-of-care molecular platform and test kits to the UK NHS, enabling rapid bedside genetic testing for neonatal antibiotic safety and stroke antiplatelet therapy selection.
Ownership category
akta.pro rank

Genedrive industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHSABALAO
Pharmacogenomics-Informed Medication Optimization Support
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support

Keywords

  • Pharmacogenetic testing
  • Molecular diagnostics
  • Point-of-care testing
  • Personalised medicine
  • Genetic test kits

Where Genedrive is headquartered

Location

Headquarters

HQ city
Manchester
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Genedrive business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Genedrive System Hardware Sales: Sale of the Genedrive molecular diagnostic instrument/platform to healthcare institutions. The system serves as the hardware platform upon which test kits are run.
  2. Test Kit Consumables: Recurring sales of MT-RNR1 ID Kit and CYP2C19 ID Kit test cartridges/consumables to NHS and healthcare customers as they conduct ongoing patient testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Genedrive product offering

Product offering

Core offering

Genedrive develops and commercialises a point-of-care molecular diagnostic platform (the Genedrive® System) that runs single-use pharmacogenetic test cartridges. Its two flagship kits — the MT-RNR1 ID Kit for personalised antibiotic selection in neonatal intensive care and the CYP2C19 ID Kit for personalised antiplatelet therapy in stroke — are sold to NHS trusts and other healthcare institutions, delivering genetic results in approximately one hour at the bedside.

Product overview

Genedrive is a pharmacogenetic testing company offering a point-of-care molecular diagnostic platform (Genedrive® System) with two flagship test kits: the MT-RNR1 ID Kit for personalised antibiotic treatment in neonates, and the CYP2C19 ID Kit for personalised antiplatelet treatment in stroke patients. The platform enables rapid genetic testing at the bedside within time-critical healthcare settings, with both products developed and validated in collaboration with NHS partners.

Differentiator

Problem solved

Functional benefit

Brands

  • Genedrive System: Molecular diagnostic platform for rapid pharmacogenetic testing at point of need.

Products and services

  • Genedrive® System

Quantifiable outcome

  • Results delivered in approximately 1 hour vs days for traditional lab testing

Companies that use Genedrive

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Genedrive technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Genedrive partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Manchester NHS Industry Partnership ProgrammecoreStrategic or Co-development Partner · 16 June 2023Multi-partner grant initiative to validate the CYP2C19 ID Kit in NHS settings requiring rapid genomic testing. Part of a Manchester NHS Industry Partnership Programme focused on improving time-critical diagnostics in healthcare.
  • Health Innovation ManchestercoreStrategic or Co-development PartnerStrategic partnership with Health Innovation Manchester to support sustained deployment of the MT-RNR1 test across Greater Manchester. The partnership involves academic and health partners to ensure implementation across all neonatal sites in the region.
  • University of ManchestercoreStrategic or Co-development PartnerAcademic partnership with University of Manchester for translational genomic medicine research and the NHSE Network of Excellence in Pharmacogenetics and Medicines Optimisation.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Genedrive competitors and assessment

Company assessment

Broad incumbents

  • Cepheid (bioMérieux): Leading molecular diagnostics platform (GeneXpert) widely deployed across hospitals including the NHS. Comparable as a point-of-care/hospital molecular diagnostics company; broader portfolio and deeper global footprint, but overlapping use cases in rapid genetic and infectious disease testing.
  • QIAGEN: Global molecular diagnostics and sample-preparation company with a broad pharmacogenetics and infectious disease portfolio. Comparable in underlying molecular diagnostic technology, though operates at much larger scale across both research and clinical markets.
  • BioFire Diagnostics (bioMérieux): Subsidiary of bioMérieux offering rapid syndromic and molecular diagnostics used in hospital and emergency settings. Comparable in delivering rapid, panel-based molecular diagnostic results at the point of care within clinically actionable timeframes.
  • GenMark Diagnostics (Roche): Now part of Roche, provides rapid molecular diagnostic systems (e.g., ePlex) for hospital and emergency care use. Comparable in deploying multi-analyte molecular panels at the hospital point of care, often in critical care and stroke workflows.
  • Mesa Labs: Acquired Agilent's molecular diagnostics and pharmacogenomics business (formerly GenMark Dx and others); provides clinical molecular testing platforms. Comparable in offering molecular diagnostics with pharmacogenomics focus into hospital and reference lab settings.
  • Thermo Fisher Scientific (Clinical Diagnostics): Global life sciences company with a clinical diagnostics division offering molecular testing instruments, reagents, and pharmacogenomics solutions. Comparable as a broad incumbent enabling hospital and reference-lab molecular and PGx testing at significantly larger scale.

Direct peers

  • QuantuMDx: UK-based developer of a point-of-care molecular diagnostic platform (Q-POC) with similar focus on rapid, decentralised genetic testing. Directly comparable business model and target customer base (hospitals, including NHS-adjacent markets).
  • Randox: UK-headquartered diagnostics company with point-of-care and clinical laboratory molecular testing capabilities, including pharmacogenetics offerings. Comparable as a UK diagnostics peer serving NHS and international hospital markets.
  • Spartan Bioscience: Canadian developer of a point-of-care DNA testing platform (Spartan Cube) with pharmacogenomics and infectious disease applications. Closely comparable in delivering rapid, cartridge-based molecular diagnostics at the bedside for personalised medicine use cases.

Emerging players

  • DxTerity Diagnostics: US-based molecular diagnostics company with focus on pharmacogenomics and immune-related testing. Comparable in offering clinical-grade PGx testing, though primarily centralised laboratory rather than point-of-care delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Genedrive social profiles

Digital presence

Genedrive financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genedrive leadership team

Management profile

Number of profiles

Profiles4 records

Genedrive funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genedrive M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genedrive

What does Genedrive do?

Genedrive develops and commercialises a point-of-care molecular diagnostic platform (the Genedrive® System) that runs single-use pharmacogenetic test cartridges. Its two flagship kits — the MT-RNR1 ID Kit for personalised antibiotic selection in neonatal intensive care and the CYP2C19 ID Kit for personalised antiplatelet therapy in stroke — are sold to NHS trusts and other healthcare institutions, delivering genetic results in approximately one hour at the bedside.

Is Genedrive a public or private company?

Genedrive is a public company. It is classified as public and is currently operating.

When was Genedrive founded?

Genedrive was founded in 2016. It employs 11 to 50 people.

Where is Genedrive based?

Genedrive is headquartered in Manchester, United Kingdom, in the Europe region.

How does Genedrive make money?

Two revenue lines are on record. Genedrive System Hardware Sales are the primary driver. The others are test Kit Consumables.

Who are Genedrive's main competitors?

Broad incumbents on record are Cepheid (bioMérieux), QIAGEN, BioFire Diagnostics (bioMérieux), GenMark Diagnostics (Roche), Mesa Labs and Thermo Fisher Scientific (Clinical Diagnostics). Direct peers are QuantuMDx, Randox and Spartan Bioscience. DxTerity Diagnostics is listed as an emerging player.

Does Genedrive have an API?

No public API is recorded for Genedrive.

What industry is Genedrive in?

Genedrive's product category is Molecular Diagnostics. Its primary akta.pro industry code is HSABALAO, Pharmacogenomics-Informed Medication Optimization Support. Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comWelsh hospitals extend routine genetic testing for newborns By Investing.comTwo Welsh hospital health boards will extend routine use of Genedrive's MT-RNR1 genetic test for newborns from May 1, 2026, until NICE guidance in July 2027. The test has identified over 40 critically ill babies, and NHS England expects a tender notice in January 2027 with a go-live target of July 2027.Investing.comWelsh hospitals extend routine genetic testing for newborns By Investing.comTwo Welsh hospital health boards will extend routine use of Genedrive's MT-RNR1 genetic test for newborns from May 1, 2026, until NICE guidance in July 2027. The test has identified over 40 critically ill babies, and clinical analysis from the PALOH-UK programme is underway with publication expected in October 2026.Sharecast.comDirector dealings: Genedrive CEO raises stakeGenedrive CEO Gino Miele acquired 700,000 ordinary shares at an average price of 1.38p each, totaling £9,660. The purchase gives him a 0.49% stake in the AIM-listed pharmacogenetic testing company. Shares rose 7.14% to 1.50p after the announcement.InsidermediaCorporate finance and medtech experts to join genedrive boardGenedrive has appointed Mark Winkler and Mike Fairbourn as independent non-executive directors to strengthen its board's financial and commercial expertise. This leadership change coincides with the company's strategic focus on scaling pharmacogenetic test adoption in the UK and expanding its international business.AdvfnGenedrive PLC MT-RNR1 test implemented in the NetherlandsGenedrive PLC has implemented its Genedrive® MT-RNR1 ID Kit at Erasmus MC University Medical Center in Rotterdam, Netherlands, effective 3 August 2026, enabling rapid pharmacogenetic testing to prevent antibiotic-induced hearing loss in newborns. The test identifies the MT-RNR1 genetic variant in babies before treatment with aminoglycoside antibiotics, which are commonly used for suspected neonatal sepsis. Erasmus MC's neonatal intensive care unit treats approximately 750 newborns annually and becomes the first medical center in the Netherlands to use this technology.Proactiveinvestorsgenedrive shares rise 9% as UK guideline backs its hearing loss testShares in genedrive PLC climbed 9% to 1.09p after a new UK clinical guideline published in the British Journal of Clinical Pharmacology recommended MT-RNR1 genotype testing to prevent antibiotic-induced hearing loss, specifically naming and endorsing the company's Genedrive MT-RNR1 ID Kit. The guideline, developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics, recommends point-of-care testing before administering aminoglycoside antibiotics across acute settings for patients of all ages and genetic ancestries. The company's CEO stated the kit is the only point-of-care test of its kind in routine clinical use in UK neonatal intensive care units, with NICE's Early Value Assessment also supporting its use in newborns.Markets Dailygenedrive (LON:GDR) Stock Price Crosses Below 50 Day Moving Average – Here’s Whygenedrive plc (LON:GDR) stock passed below its fifty day moving average during trading, with the stock trading as low as GBX 0.95 before closing at GBX 1. The company has a market cap of £17.26 million and a negative P/E ratio of -1.36. genedrive is a UK-based pharmacogenetic testing company developing point-of-care diagnostic platforms for emergency healthcare settings.InsidermediaFormer Westland Helicopters chairman Graham Cole appointed to Genedrive boardFormer Westland Helicopters chairman Graham Cole has been appointed as chair of Genedrive plc, a Manchester-based point of care pharmacogenetic testing company, also taking on a non-executive director role. Cole brings more than four decades of international leadership experience, having previously overseen annual revenues of approximately £4bn at Westland Helicopters and held senior positions within the AgustaWestland Group. The appointment is intended to help Genedrive accelerate adoption of its pharmacogenetic tests in the UK and internationally and execute its growth strategy.Insidermedia“The last year has seen significant commercial and operational progress” - Genedrive CEOGenedrive plc, a Manchester-based molecular diagnostics company, has reported strong commercial and operational progress for the year ending 30 June 2026, with the CEO stating the firm is in its strongest position to date. The company cited growing adoption of its CYP2C19 and MT-RNR1 ID Kits across the NHS, expanded international activities across Europe and the Middle East, and expects to report total income of approximately £1.4m in line with board expectations. Management indicated confidence in accelerating commercial adoption and creating sustainable long-term shareholder value over the next 12 months.The UKGenedrive building on impressive year of progress for its testing kitsGenedrive, a Manchester-based point of care pharmacogenetic testing company, released a trading update on July 13 for the period ended June 30, 2026, describing the year as one of significant commercial and operational progress. The company's MT-RNR1 testing kit has been used to test more than 13,000 newborn babies in clinical settings, with over 40 infants protected from irreversible lifelong bilateral hearing loss, while its CYP2C19 kit serves stroke patients.